TheraRadar
← Back
Data updated: Jun 28, 2026

XERIS

Specialty
Metabolic Execution: Excellent

XERIS is a specialty pharmaceutical company focused on Metabolic. Key products include GVOKE KIT.

1958
Since
6
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
3 Small Molecules

XERIS at a Glance

  • Strong track record with 95% execution quality across 15 trials
  • Fast trial execution (7 months median completion)

XERIS's Key Drugs

XERIS's core commercial portfolio centers on GVOKE KIT, GVOKE HYPOPEN, spanning Metabolic — its most strategically important drugs approved in the last 15 years.

GVOKE KIT
Metabolic

Hypoglycemia

Glucagon receptor Approved 2019
GVOKE HYPOPEN
Metabolic

Hypoglycemia

Glucagon receptor Approved 2019

XERIS's Recent FDA Approvals

New NDA/BLA approvals for XERIS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

XERIS's Therapeutic Areas

XERIS's approved drugs and pipeline span 1 therapeutic area, led by Metabolic, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Metabolic 100%
1 drugs Phase 3: 4 Phase 2: 3

XERIS's Top Competitors

XERIS's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Merck big-pharma
Metabolic
Baxter specialty
Metabolic
Johnson & Johnson big-pharma
Metabolic
OTSUKA ICU MEDCL specialty
Metabolic
GSK big-pharma
Metabolic

XERIS Pipeline Snapshot

XERIS has 7 active clinical programs from ClinicalTrials.gov — 4 Phase 3, 3 Phase 2 and 0 Phase 1.

4
Phase 3
3
Phase 2
0
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • GVOKE KIT leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Metabolic pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 4/4 completed
  • • Speed: 7 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges